Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS Rapporto sulle azioni

Cap. di mercato: US$5.4b

Ionis Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Ionis Pharmaceuticals ha un patrimonio netto totale di $662.5M e un debito totale di $1.8B, che porta il suo rapporto debito/patrimonio netto a 275.7%. Le sue attività totali e le sue passività totali sono rispettivamente $3.1B e $2.4B.

Informazioni chiave

275.7%

Rapporto debito/patrimonio netto

US$1.83b

Debito

Indice di copertura degli interessin/a
ContantiUS$2.49b
Patrimonio nettoUS$662.47m
Totale passivitàUS$2.42b
Totale attivitàUS$3.08b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 07
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Nov 16
A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Aug 03
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

May 05
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Jan 20
Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Ionis: 2 Drug Advancements With Potential Firsts

Aug 29

Ionis Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $2.7B ) di IONS superano le sue passività a breve termine ( $304.6M ).

Passività a lungo termine: Le attività a breve termine di IONS ( $2.7B ) superano le sue passività a lungo termine ( $2.1B ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: IONS ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di IONS è aumentato da 43.8% a 275.7% negli ultimi 5 anni.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: IONS ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: Dati insufficienti per determinare se IONS ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.


Scoprire le aziende sane